作者:Nouri Neamati、Zhaiwei Lin、Rajeshri G. Karki、Ann Orr、Kiriana Cowansage、Dirk Strumberg、Godwin C. G. Pais、Johannes H. Voigt、Marc C. Nicklaus、Heather E. Winslow、He Zhao、Jim A. Turpin、Jizu Yi、Anna Marie Skalka、Terrence R. Burke,、Yves Pommier
DOI:10.1021/jm0201417
日期:2002.12.1
immunodeficiency virus type 1 integrase (HIV-1 IN) is an essential enzyme for effective viral replication. Therefore, IN inhibitors are being sought for chemotherapy against AIDS. We had previously identified a series of salicylhydrazides as potent inhibitors of IN in vitro (Neamati, N.; et al. J. Med. Chem. 1998, 41, 3202-3209.). Herein, we report the design, synthesis, and antiviral activity of three novel
人类免疫缺陷病毒1型整合酶(HIV-1 IN)是有效病毒复制的必需酶。因此,正在寻求IN抑制剂用于抗AIDS的化学疗法。我们先前已经鉴定了一系列水杨酰肼作为体外IN的有效抑制剂(Neamati,N .;等人,J.Med.Chem.1998,41,3202-3209。)。在这里,我们报告了三种新型巯基水杨酰肼(MSH)衍生物的设计,合成和抗病毒活性。MSH对IN催化核心结构域有效,并抑制IN与HIV LTR DNA的结合。它们还抑制了IN-DNA预装配复合物中IN的催化活性。定点诱变和分子建模研究表明,MSH与半胱氨酸65结合并在HIV-1 IN的活性位点螯合Mg(2+)。与水杨酰肼相反,MSH的细胞毒性低300倍,并具有抗病毒活性。它们在基于Mg(2+)的测定中也很活跃,而水杨酰肼对IN的抑制作用则严格取决于Mn(2+)。另外,在基于靶标和基于细胞的测定中,MSH对其他逆转录病毒靶标(包括